Back to Agenda
Preference Studies in Regulatory and Payers' Decisions: Are We Ready?
Session Chair(s)
Francesco Pignatti, MD
Scientific Adviser for Oncology, European Medicines Agency, Netherlands
Isabelle Huys, PHARMD, PHD, MPHARM
Professor, KU Leuven, Belgium
The ICH has announced upcoming guidance development on patient preference studies. This session brings together different stakeholders to discuss the state of play and recommendations for patient preference studies in the regulatory and health technology decision context. IN particular, the session focuses on the role of preference studies in different decisions, methodological challenges and opportunities, and expectations from the patient community for inclusion of preference studies in regulatory submissions.
Speaker(s)
Jorien Veldwijk, PHD, MSC
, Erasmus University Rotterdam, Netherlands
Patient Preferences Along the Drug Lifecycle
Antonella Cardone
Director, Cancer Patients Europe, Belgium
Should Patient Preferences Be Required in Drug Applications?
Sheila Dickinson, MSC
Director, Patient Experience Data Science, Novartis Pharma AG, Switzerland
Challenges and Opportunities from an Industry Perspective
Irina Cleemput, PHD
Scientific Programme Director, Belgian Health Care Knowledge Centre (KCE), Belgium
Panelist
Douwe Postmus, PHD, MSC
Assistant Professor & Seconded National Expert, University Medical Center Groningen & EMA, Netherlands
Panelist
Robert Sauermann, DrMed
Deputy Head of Department of Pharmaceutical Affairs, Austrian Federation of Social Insurances, Austria
Panelist
Have an account?